局部晚期-话题@MedSci

#局部晚期#

176篇内容 | 3330人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1650809, encodeId=4e27165080922, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Clinical Nutrition：身体成分参数可以预测接受新辅助治疗后局部晚期胃癌患者预后, objectType=article, longId=213692, objectId=780621369207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=780621369207, replyNumber=0, likeNumber=71, createdTime=2022-04-20, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=780621369207, moduleTitle=Clinical Nutrition：身体成分参数可以预测接受新辅助治疗后局部晚期胃癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=780621369207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650822, encodeId=9bb91650822c9, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Front Oncol：术前放疗(RT)和治疗前CEA水平跟局部晚期直肠癌（LARC）患者预后的关系, objectType=article, longId=218486, objectId=f89c21848669, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f89c21848669, replyNumber=0, likeNumber=65, createdTime=2022-08-07, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f89c21848669, moduleTitle=Front Oncol：术前放疗(RT)和治疗前CEA水平跟局部晚期直肠癌（LARC）患者预后的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f89c21848669)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650845, encodeId=8cc816508455d, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=J Clin Oncol：JCOG1008研究表明高复发风险局部晚期头颈癌术后顺铂每周+放疗不劣效于顺铂三周方案, objectType=article, longId=300283, objectId=9daa30028368, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9daa30028368, replyNumber=0, likeNumber=73, createdTime=2022-04-19, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9daa30028368, moduleTitle=J Clin Oncol：JCOG1008研究表明高复发风险局部晚期头颈癌术后顺铂每周+放疗不劣效于顺铂三周方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9daa30028368)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650840, encodeId=6c311650840e3, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, objectType=article, longId=295185, objectId=293529518574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=293529518574, replyNumber=0, likeNumber=82, createdTime=2022-11-06, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=293529518574, moduleTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=293529518574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650813, encodeId=637b16508137a, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！, objectType=article, longId=214810, objectId=c1e621481097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e621481097, replyNumber=0, likeNumber=57, createdTime=2022-07-02, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e621481097, moduleTitle=Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e621481097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650846, encodeId=761416508460a, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=J Clin Oncol：中科院&协和 | 术前短程放疗+化疗方案或可替代局部晚期直肠癌的标准长程放化疗方案！, objectType=article, longId=300486, objectId=097730048604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=097730048604, replyNumber=0, likeNumber=83, createdTime=2022-09-13, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=097730048604, moduleTitle=J Clin Oncol：中科院&协和 | 术前短程放疗+化疗方案或可替代局部晚期直肠癌的标准长程放化疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=097730048604)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650828, encodeId=00411650828f8, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, objectType=article, longId=220865, objectId=1061220865c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1061220865c1, replyNumber=0, likeNumber=69, createdTime=2022-07-08, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1061220865c1, moduleTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1061220865c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650830, encodeId=505616508307a, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！, objectType=article, longId=221421, objectId=c3fc22142171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3fc22142171, replyNumber=0, likeNumber=94, createdTime=2022-05-01, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3fc22142171, moduleTitle=JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3fc22142171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650805, encodeId=e176165080570, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , objectType=article, longId=212089, objectId=fc5c2120893c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc5c2120893c, replyNumber=0, likeNumber=58, createdTime=2022-03-29, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc5c2120893c, moduleTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc5c2120893c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650815, encodeId=fff1165081545, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）, objectType=article, longId=215628, objectId=4ff021562880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff021562880, replyNumber=0, likeNumber=142, createdTime=2021-10-12, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff021562880, moduleTitle=JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff021562880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650807, encodeId=786d165080e12, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JTO：吉非替尼同步胸腔放疗治疗不可切除的EGFR突变局部晚期非小细胞肺癌, objectType=article, longId=213319, objectId=eb9e21331927, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb9e21331927, replyNumber=0, likeNumber=51, createdTime=2021-10-05, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb9e21331927, moduleTitle=JTO：吉非替尼同步胸腔放疗治疗不可切除的EGFR突变局部晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb9e21331927)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650843, encodeId=493e1650843f3, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？, objectType=article, longId=299913, objectId=686d29991338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686d29991338, replyNumber=0, likeNumber=63, createdTime=2022-07-10, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686d29991338, moduleTitle=Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686d29991338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650823, encodeId=301e1650823f5, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Front Oncol：局部晚期鼻咽癌三种诱导化疗的疗效和毒性：10年随访结果, objectType=article, longId=218614, objectId=3d32218614c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d32218614c3, replyNumber=0, likeNumber=89, createdTime=2022-03-18, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d32218614c3, moduleTitle=Front Oncol：局部晚期鼻咽癌三种诱导化疗的疗效和毒性：10年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d32218614c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650803, encodeId=5fc81650803cd, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet oncol：Cemiplimab在局部晚期基底细胞癌中的抗肿瘤活性令人可期, objectType=article, longId=211377, objectId=f1712113e75f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1712113e75f, replyNumber=0, likeNumber=61, createdTime=2021-05-28, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1712113e75f, moduleTitle=Lancet oncol：Cemiplimab在局部晚期基底细胞癌中的抗肿瘤活性令人可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1712113e75f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650804, encodeId=24a116508044d, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet Oncology：局部晚期头颈肿瘤的放化疗：一项个体患者数据网状荟萃分析 , objectType=article, longId=211726, objectId=629e211e265b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=629e211e265b, replyNumber=0, likeNumber=79, createdTime=2021-06-14, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=629e211e265b, moduleTitle=Lancet Oncology：局部晚期头颈肿瘤的放化疗：一项个体患者数据网状荟萃分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=629e211e265b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650827, encodeId=cfb1165082e6b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Clin Cancer Res：采用抗CCR4单抗Mogamulizumab联合纳武单抗治疗局部晚期或转移性实体瘤, objectType=article, longId=220589, objectId=24ea2205893f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24ea2205893f, replyNumber=0, likeNumber=69, createdTime=2022-06-07, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24ea2205893f, moduleTitle=Clin Cancer Res：采用抗CCR4单抗Mogamulizumab联合纳武单抗治疗局部晚期或转移性实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24ea2205893f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650833, encodeId=bc5f1650833a6, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=DCR：盆腔外侧淋巴结清扫术后局部晚期直肠癌的复发危险因素分析, objectType=article, longId=265011, objectId=89fb265011c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89fb265011c9, replyNumber=0, likeNumber=76, createdTime=2022-04-13, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89fb265011c9, moduleTitle=DCR：盆腔外侧淋巴结清扫术后局部晚期直肠癌的复发危险因素分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89fb265011c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650836, encodeId=babf16508363d, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JAMA Netw Open：腹腔镜全胃切除+保脾的脾门淋巴结切除（LSTG）治疗局部晚期近端胃癌的疗效：CLASS-04, objectType=article, longId=292635, objectId=cc7d292635ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc7d292635ea, replyNumber=0, likeNumber=69, createdTime=2022-12-02, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc7d292635ea, moduleTitle=JAMA Netw Open：腹腔镜全胃切除+保脾的脾门淋巴结切除（LSTG）治疗局部晚期近端胃癌的疗效：CLASS-04, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc7d292635ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650811, encodeId=a94616508117f, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析, objectType=article, longId=213741, objectId=328f213e41bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=328f213e41bd, replyNumber=0, likeNumber=66, createdTime=2021-10-10, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=328f213e41bd, moduleTitle=Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=328f213e41bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650834, encodeId=a0551650834c7, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=直播回放：围手术期及局部晚期NSCLC免疫治疗进展, objectType=article, longId=292397, objectId=ddcf29239ee4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddcf29239ee4, replyNumber=0, likeNumber=38, createdTime=2022-11-17, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddcf29239ee4, moduleTitle=直播回放：围手术期及局部晚期NSCLC免疫治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddcf29239ee4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

局部晚期

2020-05-29

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Clinical Nutrition：身体成分参数可以预测接受新辅助治疗后局部晚期胃癌患者预后

2022-04-20

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Front Oncol：术前放疗(RT)和治疗前CEA水平跟局部晚期直肠癌（LARC）患者预后的关系

2022-08-07

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

J Clin Oncol：JCOG1008研究表明高复发风险局部晚期头颈癌术后顺铂每周+放疗不劣效于顺铂三周方案

2022-04-19

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性

2022-11-06

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！

2022-07-02

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

J Clin Oncol：中科院&协和 | 术前短程放疗+化疗方案或可替代局部晚期直肠癌的标准长程放化疗方案！

2022-09-13

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析

2022-07-08

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！

2022-05-01

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验

2022-03-29

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）

2021-10-12

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JTO：吉非替尼同步胸腔放疗治疗不可切除的EGFR突变局部晚期非小细胞肺癌

2021-10-05

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？

2022-07-10

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Front Oncol：局部晚期鼻咽癌三种诱导化疗的疗效和毒性：10年随访结果

2022-03-18

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet oncol：Cemiplimab在局部晚期基底细胞癌中的抗肿瘤活性令人可期

2021-05-28

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet Oncology：局部晚期头颈肿瘤的放化疗：一项个体患者数据网状荟萃分析

2021-06-14

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Clin Cancer Res：采用抗CCR4单抗Mogamulizumab联合纳武单抗治疗局部晚期或转移性实体瘤

2022-06-07

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

DCR：盆腔外侧淋巴结清扫术后局部晚期直肠癌的复发危险因素分析

2022-04-13

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JAMA Netw Open：腹腔镜全胃切除+保脾的脾门淋巴结切除（LSTG）治疗局部晚期近端胃癌的疗效：CLASS-04

2022-12-02

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析

2021-10-10

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

直播回放：围手术期及局部晚期NSCLC免疫治疗进展

2022-11-17

科室
- - 订阅+
  - 更多科室
工具
服务